DOI QR코드

DOI QR Code

Root bark extract of Cudrania tricuspidata reduces LPS-induced inflammation in macrophages of atherogenic mice

  • Lee, Mi-Ran (Dept. of Biomedical Laboratory Science, Jungwon University)
  • Received : 2020.10.06
  • Accepted : 2020.10.26
  • Published : 2020.10.30

Abstract

In this paper, we propose to evaluate the potential anti-inflammatory properties of root bark extract of Cudrania (C.) tricuspidata on lipopolysaccharide (LPS)-induced inflammation in macrophages of apolipoprotein E (ApoE) knockout (ApoE-/-) mice, murine model of atherosclerosis. Atherosclerosis is a chronic vascular inflammatory disease. C. tricuspidata is a small tree of the Moraceae family and its extract has anti-inflammatory activities. However, its role in the progress of atherosclerosis is not yet clear. To determine anti-inflammatory effects of C. tricuspidata in atherogenesis, we applied LPS in peritoneal macrophages of ApoE-/- mice and measured cell viability by CCK-8 and expression of pro-inflammatory cytokines by qRT-PCR following treatment with root bark extract of C. tricuspidata. Research data was expressed as differences between the cells treated with LPS and root bark extract and the cells treated with LPS alone (control) by a two-tailed non-parametric Mann-Whitney U-test using GraphPad Instat program. No cytotoxic effect was observed when the cells were treated with the extract at concentrations ≤ 100 ㎍/mL. The expression of inflammatory cytokines, including MCP-1, IL-1β, IFN-γ, TNF-α, and IL-6 were inhibited by the extract. These results indicated that the extract has an anti-inflammatory effect and therefore a possible role in the treatment of atherosclerosis.

동맥경화증은 동맥 내피세포의 손상으로 인해 내막층에 지질이 축적되어 발생 되는 염증성 질환으로 동맥 내막에 침윤되는 백혈구와 백혈구에서 분비되는 전염증성 싸이토카인에 의해 죽종형성이 시작된다. 꾸지뽕은 뽕나무과의 작은 나무로 그 추출물은 항염증, 항산화, 항암의 효과를 가지고 있다. 그러나, 동맥경화증에서 효능은 명확하게 연구되지 않았다. 본 연구에서는 동맥경화증의 초기 진행에서 꾸지뽕의 항염증 효과를 알아보고자 꾸지뽕 뿌리의 추출물을 수득하였고, 동맥경화증의 동물 모델인 ApoE 결손 생쥐에서 복강대식세포를 분리하였다. 분리된 복강대식세포에 LPS로 염증반응을 유발하고 꾸지뽕 뿌리 추출물을 처리하였을 때 100㎍/ml 이하의 농도에서 세포 생존율의 변화가 관찰되지 않아 이 농도를 추가 실험을 위한 유효 농도로 설정하였다. 또한, LPS에 의해 증가한 염증 싸이토카인(MCP-1, IL-1β, IFN-γ, TNF-α, IL-6)의 발현이 꾸지뽕 뿌리 추출물에 의해 감소하였다. 따라서, 꾸지뽕 뿌리 추출물은 동맥경화의 잠재적 위험성을 가지고 있는 대식세포에서 항염증 효과를 나타내어 동맥경화증의 치료제 개발에 이용 가능할 것이다.

Keywords

References

  1. Zaman S, Goldberger JJ, Kovoor P., "Sudden Death Risk-Stratifi cation in 2018-2019: The Old and the New" Heart Lung Circ. Vol. 28, No. 1, pp. 57-64, Jan 2019. DOI: 10.1016/j.hlc.2018.08.027
  2. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013", Lancet. Vol. 385, No. 9963, pp. 117-171, Jan 2015. DOI: 10.1016/S0140-6736(14)61682-2
  3. Statistics Korea. 2019. Cause-of-death statistics in 2019 pp. 1-56
  4. Gallino A, Aboyans V, Diehm C, et al. "Non-coronary atherosclerosis", Eur Heart J. Vol. 35, No. 17, pp. 1112-1119, May 2014. DOI: 10.1093/eurheartj/ehu071
  5. Gimbrone MA Jr, Garcia-Cardena G. "Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis", Circ Res. Vol. 118, No. 4, pp. 620-636, Feb 2016. DOI: 10.1161/CIRCRESAHA.115.306301
  6. Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD., "Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation", Oxid Med Cell Longev. Vol. 2019, pp. 8563845, July 2019. DOI: 10.1155/2019/8563845
  7. Ridker, P.M. "Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin", Eur. Heart J. Vol. 37, No. 22, pp. 1720-1722, Feb 2016. DOI: 10.1093/eurheartj/ehw024
  8. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. "Mechanisms of foam cell formation in atherosclerosis", J Mol Med (Berl). Vol. 95, No. 11, pp. 1153-1165, Nov 2017. DOI: 10.1007/s00109-017-1575-8
  9. Malekmohammad K, Sewell RD, Rafieian-Kopaei M, "Antioxidants and Atherosclerosis: Mechanistic Aspects", Biomolecules. Vol. 9, No. 8, pp.301, July 2019. DOI: 10.3390/biom9080301
  10. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. "Cholesterol Treatment Trialists'(CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials", Lancet. Vol. 380, No. 9841, pp. 581-590. May 2012. DOI: 10.1016/S0140-6736(12)60367-5
  11. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med. Vol. 359, No. 21, pp. 2195-2207, Nov 2008. DOI: 10.1056/NEJMoa0807646
  12. Guyton JR, Bays HE, Grundy SM, et al. "An assessment by the statin intolerance panel", J Clin Lipidol. Vol. 8, No. 3, pp. S72-81, May 2014. DOI: 10.1016/j.jacl.2014.03.002
  13. Sung J, Kim SH, Song HR, et al. "Lipid-lowering treatment practice patterns in Korea: comparison with the data obtained from the CEPHEUS pan-Asian study", J Atherocler Thromb. Vol. 21, No. 11, pp. 1219-1227, July 2014. DOI: 10.5551/jat.23242
  14. Robert M., Merel L., Roger R., Douwe D,, Erik S., et al. "PCSK9 inhibitors in clinical practice: Delivering on the promise?", Atherosclerosis. Vol. 270, pp. 205-210, Mar 2018. DOI: 10.1016/j.atherosclerosis.2017.11.027
  15. Xin LT., Yue SJ., Fan YC., Wu JS., Yan D., Guan HS, et al. "Cudrania tricuspidata: an updated review on ethnomedicine, phytochemistry and pharmacology", RSC Adv. Vol. 7, No. 51, pp. 31807-31832, Dec 2017. DOI: org/10.1039/C7RA04322H
  16. Jo YH., Kim SB., Liu Q., Hwang BY., Lee MK. "Prenylated xanthones from the roots of Cudrania tricuspidata as inhibitors of lipopolysaccharide-stimulated nitric oxide production" Arch Pharm. Vol. 350, No. 1, pp. e1600263, Jan 2017. DOI: 10.1002/ardp.201600263
  17. Cho SS., Yang JH., Seo KH., Shin SM., Park EY., Cho SS, et al. "Cudrania tricuspidata extract and its major constituents inhibit oxidative stress-induced liver injury" J Med Food. Vol. 22, No. 6, pp. 602-613, June 2019. DOI: 10.1089/jmf.2018.4322
  18. Jiang X, Cao C, Sun W, Chen Z, Li X, et al. "Scandenolone from Cudrania tricuspidata fruit extract suppresses the viability of breast cancer cells (MCF-7) in vitro and in vivo", Food Chem Toxicol. Vol. 126, pp. 56-66, Feb 2019. DOI: 10.1016/j.fct.2019.02.020
  19. Jo YH., Kim SB., Ahn JH., Turk A., Kwon EB., Kim MO, et al. "Xanthones from the stems of Cudrania tricuspidata and their inhibitory effects on pancreatic lipase and fat accumulation. Bioorg Chem. Vol. 92, pp. 103234, Nov 2019. DOI: 10.1016/j.bioorg.2019.103234
  20. Lee SB, Shin JS, Han HS, Lee HH, Park JC, et al. "Kaempferol 7-O-$\beta$-D-glucoside isolated from the leaves of Cudrania tricuspidata inhibits LPS-induced expression of pro-inflammatory mediators through inactivation of $NF-{\kappa}B$, AP-1, and JAK-STAT in RAW 264.7 macrophages", Chem Biol Interact. Vol. 284, pp. 101-111, Mar 2018. DOI: 10.1016/j.cbi.2018.02.022
  21. Park KH., Park YD., Han JM. Im KR., Lee BW., et al. "Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata", Bioorg Med Chem Lett. Vol. 16, No. 21, pp. 5580-5583, Nov 2006. DOI: 10.1016/j.bmcl.2006.08.032
  22. Li X, Yao Z, Jiang X, Sun J, Ran G, et al. "Bioactive compounds from Cudrania tricuspidata: A natural anticancer source", Crit Rev Food Sci Nutr. Vol. 60, No. 3, pp. 494-514. Dec 2020. DOI: 10.1080/10408398.2018.1541866
  23. Fujimoto T, Hano Y, Nomura T. "Components of Root Bark of Cudrania tricuspidata l.1,2 Structures of Four New Isoprenylated Xanthones, Cudraxanthones A, B, C and D", Planta Med. Vol. 50, No. 3, pp. 218-221, June 1984. DOI: 10.1055/s-2007-969682
  24. Kim OK., Nam DE., Jun W., Lee J. "Anti-wrinkle Activity of a Curdrania tricuspidata Extract on Ultraviolet-induced Photoaging", J Korean Soc Food Sci Nutr. Vol. 42, No. 4, pp. 608-614, June 2013. DOI: 10.3746/jkfn.2013.42.4.608
  25. Lee T, Kwon J, Lee D, Mar W. "Effects of Cudrania tricuspidata Fruit Extract and Its Active Compound, 5,7,3',4'-Tetrahydroxy-6, 8-diprenylisoflavone, on the High- Affinity IgE Receptor-Media ted Activation of Syk in Mast Cells", J Agric Food Chem. Vol. 63, No. 22, pp. 5459-5467, June 2015. DOI: 10.1021/acs.jafc.5b00903
  26. Cheng N, Liang Y, Du X, Ye RD. "Serum amyloid A promotes LPS clearance and suppresses LPS-induced inflammation and tissue injury ," EMBO Rep. Vol. 19 No. 10, pp. e45517, Oct 2018. DOI: 10.15252/embr.201745517
  27. Lin J, Kakkar V, Lu X. "Impact of MCP-1 in atherosclerosis", Curr Pharm Des. Vol. 20, No. 28, pp.4580-4588, Jan 2014. DOI: 10.2174/1381612820666140522115801
  28. D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A. & Clark, G. C. Targeting the "cytokine storm" for therapeutic benefit. Clin. Vaccine Immunol. Vol. 20, No. 3 pp. 319-327, Jan 2013. DOI: 10.1128/CVI.00636-12
  29. Bartekova M,, Radosinska J, Jelemensky M, Dhalla SD. "Role of cytokines and inflammation in heart function during health and disease" Heart Fail Rev. Vol. 23, No. 5, pp. 733-758, Sep 2018. DOI: 10.1007/s10741-018-9716-x
  30. Hartman J, Frishman WH. "Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy", Cardiol Rev. Vol. 22, No. 3, pp. 147-151, May-June 2014. DOI: 10.1097/CRD.0000000000000021
  31. Park JG and Oh GT. "Current pharmacotherapies for atherosclerotic cardiovascular diseases", BMB Rep. Vol. 44. No. 8, pp. 497-505, Aug 2011. DOI: 10.5483/bmbrep.2011.44.8.497
  32. Koh BS, Park HJ, Kim SR, Monn IJ, Leem D, et al. "Adverse drug reactions after taking the extract of Cudrania tricuspidata", Allergy Asthma Respir Dis. Vol. 2, No. 5, pp. 387-390, Jan 2014. DOI: 10.4168/aard.2014.2.5.387
  33. Chang SL, Huang YH, Yang CH, Hu S, Hong HS. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol Vol. 88, pp. 363-365, Jan 2008. DOI: 10.2340/00015555-0438